Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine plus oxaliplatin in pediatric relapsed/refractory neuroblastoma and miscellaneous solid non-CNS tumors
2005-005219-36Phase 2Active
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2005
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and oxaliplatin in neuroblastoma and Nonhematologic neoplasms, sponsored by Eli Lilly and Company. Primary endpoints: Objective response rate in neuroblastoma cohort and Descriptive antitumor activity in miscellaneous solid non-CNS tumor cohort. Started Dec 2005; status: active.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
neuroblastomaNonhematologic neoplasms
Beyond the preview
Go deeper on 2005-005219-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005219-36.